* Cross Country Healthcare Inc CCRN.OQ CCRN.O is
expected
to show a fall in quarterly revenue when it reports results on
May 1 for the period ending March 31 2024
* The Boca Raton Florida-based company is expected to
report a
39.9% decrease in revenue to $374.089 million from $622.71
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.The company's guidance on February
21 2024, for the period ended March 31, was for revenue between
370.00 million and 380.00 million.
* LSEG's mean analyst estimate for Cross Country Healthcare
Inc
is for earnings of 17 cents per share. The company's EPS
guidance on February 21 2024, for the period ended March 31, was
between 0.15 and 0.25
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cross
Country
Healthcare Inc is $19.00, above its last closing price
of $17.55.
The company's guidance on February 21 2024 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between 370 million and 18 million.The
company's guidance on February 21 2024 for the period ended
March 31 was for gross profit margin between 21% and 21.5%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.27 0.27 0.29 Beat 6.1
Sep. 30 2023 0.41 0.41 0.39 Missed -4.2
Jun. 30 2023 0.61 0.61 0.69 Beat 13.3
Mar. 31 2023 0.75 0.75 0.84 Beat 12.4
Dec. 0.89 0.89 1.09 Beat 21.9
31 2022
Sep. 30 2022 0.96 0.95 1.07 Beat 12.6
Jun. 30 2022 1.35 1.35 1.40 Beat 3.8
Mar. 31 2022 1.34 1.31 1.70 Beat 29.3
This summary was machine generated April 30 at 00:54 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)